Ignite Creation Date:
2024-05-05 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00511823
Status:
COMPLETED
Last Update Posted:
2017-08-03
First Post:
2007-08-02
Brief Title:
The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron Granisetron or Rosiglitazone in Subjects
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
An Open-Label Three-Part Two Period Single Sequence Study to Assess the Pharmacokinetic Interaction Between Repeat Doses of Oral Casopitant and Repeat Oral Doses of Dolasetron Granisetron or Rosiglitazone When Co-Administered in Healthy Adult Subjects
Status:
COMPLETED
Status Verified Date:
2017-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This A Three-Part Drug-Drug Interaction Study To Evaluate Effects of Casopitant On Dolasetron Granisetron or Rosiglitazone When Co-Administered in Healthy Adults
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None